Adalvo has submitted the DCP for Palbociclib film-coated tablets, reinforcing its commitment to expanding its oncology portfolio. Approval is expected in November 2025.
Supported by Adalvo’s focused IP strategy, this submission is part of Adalvo’s aim to address the global demand for advanced cancer treatments. Alongside Palbociclib, Adalvo’s breast cancer portfolio includes Fulvestrant (launched), Eribulin (targeted for Day 1 launch after the expiry of relevant IP rights), and Ribociclib and Elacestrant, which are in the development phase.
Based on the reference brand Ibrance, Palbociclib is indicated for the treatment of HR-positive, HER2-negative breast cancer. Ibrance reached $5.8 billion in global sales in 2023, with a 3-year CAGR of 4%, according to IQVIA.
At Adalvo, there are no half-measures – we are always on target. When the goal is to have a strong impact in oncology care, you need a team committed to driving results.
Partner with Adalvo to strengthen your oncology portfolio and broaden patient access.